A Comparison of Dabigatran With Warfarin for Stroke Prevention in Atrial Fibrillation in an Asian Population
| Autor: | Dhanan Umadevan, Beni Isman Rusani, Barveen Aisha, Razali Omar, Azlan Hussin, Surinder Kaur, Zulkeflee Muhammad, Daniel Theng Sheng Eng, Rajasingam Shanmugam, Kok Wei Koh, Lingghesh Sivalingam, Lok Bin Yap, Rosila Rebo, Mohd Irwan Hashim |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Male
medicine.medical_specialty 030204 cardiovascular system & hematology Antithrombins Dabigatran Cohort Studies 03 medical and health sciences 0302 clinical medicine Asian People Internal medicine Atrial Fibrillation medicine Humans cardiovascular diseases Caucasian population Stroke Aged Retrospective Studies business.industry Warfarin Atrial fibrillation Hematology General Medicine medicine.disease Treatment Outcome Stroke prevention Asian population Cardiology Female business 030217 neurology & neurosurgery Intracranial bleeding medicine.drug |
| Zdroj: | Clinical and Applied Thrombosis/Hemostasis. 22:792-797 |
| ISSN: | 1938-2723 1076-0296 |
| Popis: | Background: The Asian population with atrial fibrillation (AF) have a higher risk of stroke than the caucasian population and a higher risk of intracranial bleeding when anticoagulated with warfarin. There are few real-world studies comparing the efficacy of non-vitamin K antagonist oral anticoagulants (NOACs) and warfarin among Asian patients to assess its outcomes of ischemic stroke and hemorrhagic stroke. Methods: A retrospective cohort study of 1000 patients on dabigatran and warfarin from 2009 to 2013. Results: Data were available for 500 patients on dabigatran and 500 patients on warfarin. The average follow-up duration was 315 ± 280 days in the dabigatran group and 355 ± 232 in the warfarin group. The time in therapeutic range (TTR) was 53.2% in the warfarin-treated group, with 32.8% of patients in the subtherapeutic international normalized ratio range of Conclusion: There were similar rates of efficacy for outcomes of ischemic CVA, hemorrhagic CVA, and bleeding when comparing dabigatran with warfarin. Our study shows that despite similar efficacy, suboptimal TTR rates and inconveniences with warfarin demonstrate that NOACs are preferred for stroke prevention in AF. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|